Pfizer, Strategy and Innovation
Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development
Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities.
2hon MSN
Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.
Pfizer's strategic weaknesses mount and the stock became overvalued after the recent rally. Read more to see our analysis on ...
Pfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its ...
Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...
AM Best has confirmed the financial strength rating of A (Excellent) and the long-term issuer credit rating of a+ (Excellent) ...
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs ...
Pfizer has agreed to pay $25.5 million to resolve claims that its predecessor Wyeth conspired with rival Teva to delay ...
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results